Corrections:
Correction: Tumor-associated macrophages promote tumor metastasis via the TGF-β/SOX9 axis in non-small cell lung cancer
1 The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
2 Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
3 Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China
4 Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
5 Department of Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, China
6 Department of Oncology, The First Affiliated Hospital of Qiqihar Medical College, Qiqihar, China
Published: December 29, 2020
This article has been corrected: Due to errors in image selection, the pictures of H1299 cell morphology treated with recombinant TGF-β and TGF-β receptor inhibitor in Figure 5A are incorrect. When preparing the results, the control group data was mistakenly copied and presented as the treatment group. The corrected Figure 5 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
Original article: Oncotarget. 2017; 8:99801–99815. DOI: https://doi.org/10.18632/oncotarget.21068.
Figure 5: TGF-β increased SOX9 expression and induced transformation into an EMT-like phenotype in lung cancer cells. (A) Changes in lung cancer cell morphology after recombinant TGF-β (10ng/ml) or TGF-β receptor inhibitor (TGFR I, SD208, 1μM) was added to A549 and H1299 cell culture systems for 24 or 48 h. (B–C) Changes in SOX9, E-cadherin, and vimentin protein (B) and mRNA (C) levels in lung cancer cells after recombinant TGF-β or TGFR I was added to A549 and H1299 cell culture systems for 48 h. ***p < 0.01, mean ± SEM.